Lifecore Biomedical (NASDAQ:LFCR) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Head-To-Head Review

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Lifecore Biomedical (NASDAQ:LFCR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Valuation & Earnings

This table compares Recordati Industria Chimica E Farmaceutica and Lifecore Biomedical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.04	$501.92 million	$2.80	20.71
Lifecore Biomedical	$128.87 million	1.23	-$40.50 million	($1.07)	-3.93

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Recordati Industria Chimica E Farmaceutica has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Recordati Industria Chimica E Farmaceutica and Lifecore Biomedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00
Lifecore Biomedical	1	1	1	0	2.00

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 54.76%. Given Lifecore Biomedical’s higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than Recordati Industria Chimica E Farmaceutica.

Summary

Recordati Industria Chimica E Farmaceutica beats Lifecore Biomedical on 10 of the 15 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.